News by community
09.01.2020 ADC Therapeutics Announces Positive Results from Pivotal Phase 2 Clinical Trial of Single Agent Loncastuximab Tesirine (ADCT-402) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Lausanne, Switzerland, January 9, 2020 – ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors, today announced positive results from the pivotal 145-patient Phase 2 clinical trial of loncastuximab tesirine (ADCT-402) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
To date, loncastuximab tesirine has achieved an overall response rate (ORR) of 45.5% (66/145 patients), including 20% complete responses and 25.5% partial responses, across a broad population of relapsed or refractory DLBCL patients, even those who are difficult to treat. Comparably, the ORR in the 183-patient Phase 1 clinical trial of loncastuximab tesirine at the initial dose used in Phase 2 was 41.4% (29/70 patients), including 21.4% complete responses and 20% partial responses. Loncastuximab tesirine has demonstrated manageable toxicity in patients with relapsed or refractory DLBCL. The most common grade ≥3 treatment-emergent adverse events in the Phase 2 clinical trial were neutropenia, thrombocytopenia and increased gamma-glutamyltransferase.